Tag

Trial Results

All articles tagged with #trial results

business14 days ago•15 min saved

Next-gen obesity drug race tightens as pivotal readouts loom

Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.

via Pharma Voice|

#business #eli-lilly #glp-1

biotechnology5 months ago•2 min saved

Biotech Stocks Drop Sharply After Disappointing Bone Disease Drug Trials

Shares of Ultragenyx and Mereo BioPharma plummeted after their Phase 3 trial for the brittle-bone disease treatment setrusumab failed to meet primary endpoints, despite secondary improvements in bone density, leading to significant market value losses and cautious outlooks from analysts.

via MarketWatch|

#biotech-stocks #biotechnology #mereo-biopharma

health9 months ago•2 min saved

Eli Lilly's forforglipron Success Spurs Global Obesity and Diabetes Treatment Approvals

Eli Lilly announced that its anti-obesity pill, orforglipron, successfully met weight-loss targets in a key diabetes trial, reducing body weight by 10.5% on average, which boosts its plans for FDA approval and intensifies competition with Novo Nordisk in the weight-loss drug market.

via Financial Times|

#diabetes #eli-lilly #health

business9 months ago•1 min saved

Eli Lilly's Obesity Pill Shows Promising Weight Loss but Shares Fall

Eli Lilly's obesity drug underperformed in clinical trials, leading to a 14% drop in its shares, disappointing investors and raising concerns about its future prospects.

via Financial Times|

#business #eli-lilly #obesity-pill

business11 months ago•2 min saved

Amgen's Weight-Loss Drug Faces Challenges and Adjustments in Trials

Amgen's shares dropped after disappointing trial results for its weight-loss drug MariTide, which showed high discontinuation rates due to gastrointestinal side effects, especially at higher doses, despite promising efficacy in weight loss; the company plans to adjust its Phase 3 trial strategy to mitigate these issues.

via Barron's|

#amgen #business #gastrointestinal-side-effects

health2 years ago•1 min saved

"Wegovy: A Game-Changer in Heart Disease Prevention, Boosting Novo Nordisk's Stock"

Novo Nordisk, the maker of the weight-loss drug Wegovy, shared data from a major trial showing that the drug lowers the risk of adverse cardiovascular events by 20%. The trial involved over 17,000 participants and measured data over a five-year period. The 2.4 mg dosage of Wegovy was found to be safe and well-tolerated. The announcement of the trial results caused Novo Nordisk's shares to surge by over 16%.

via Forbes|

#cardiovascular-events #health #novo-nordisk